Drug Profile


Alternative Names: P-144; Peptide 144

Latest Information Update: 09 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Digna Biotech; University of Navarra
  • Developer Avadel Pharmaceuticals; Digna Biotech; ISDIN; University of Navarra
  • Class Peptides
  • Mechanism of Action Apoptosis stimulants; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Age-related macular degeneration; Corneal ulcer; Dry eyes; Systemic scleroderma

Highest Development Phases

  • Phase II Systemic scleroderma
  • Preclinical Age-related macular degeneration; Corneal ulcer; Dry eyes; Glioblastoma; Pulmonary fibrosis
  • Discontinued Actinic keratosis; Burns; Fibrosis; Keloids; Psoriasis; Skin cancer

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 12 Oct 2016 Phase II development in Systemic scleroderma is ongoing in Germany, Hungary, italy, Poland, Spain and United Kingdom
  • 16 Apr 2016 Preclinical pharmacodynamics data in Glioblastoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top